5HTA Stock Overview
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Harpoon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.80 |
| 52 Week High | US$21.20 |
| 52 Week Low | US$4.86 |
| Beta | 2.1 |
| 1 Month Change | 0.97% |
| 3 Month Change | n/a |
| 1 Year Change | 230.16% |
| 3 Year Change | -87.62% |
| 5 Year Change | -80.41% |
| Change since IPO | -83.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5HTA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.8% |
| 1Y | 230.2% | -15.8% | 1.0% |
Return vs Industry: 5HTA exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 5HTA exceeded the German Market which returned 4.6% over the past year.
Price Volatility
| 5HTA volatility | |
|---|---|
| 5HTA Average Weekly Movement | 51.8% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5HTA has not had significant price volatility in the past 3 months.
Volatility Over Time: 5HTA's weekly volatility has increased from 28% to 52% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 53 | Julie Eastland | www.harpoontx.com |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications.
Harpoon Therapeutics, Inc. Fundamentals Summary
| 5HTA fundamental statistics | |
|---|---|
| Market cap | €450.35m |
| Earnings (TTM) | -€27.90m |
| Revenue (TTM) | €34.16m |
13.2x
P/S Ratio-16.1x
P/E RatioIs 5HTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5HTA income statement (TTM) | |
|---|---|
| Revenue | US$37.34m |
| Cost of Revenue | US$58.63m |
| Gross Profit | -US$21.29m |
| Other Expenses | US$9.21m |
| Earnings | -US$30.50m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | -57.02% |
| Net Profit Margin | -81.67% |
| Debt/Equity Ratio | 194.4% |
How did 5HTA perform over the long term?
See historical performance and comparison